{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:02Z","timestamp":1789726262559,"version":"4.0.1"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T00:00:00Z","timestamp":1628640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Place Outcomes Research Award"},{"name":"Cincinnati Clinical Translational Research Center"},{"name":"National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program","award":["2UL1TR001425-05A1"],"award-info":[{"award-number":["2UL1TR001425-05A1"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01 DC017867"],"award-info":[{"award-number":["R01 DC017867"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Further optimization of therapeutic drug monitoring (TDM) for aminoglycosides (AGs) is urgently needed, especially in special populations such as those with cystic fibrosis (CF), &amp;gt;50% of whom develop ototoxicity if treated with multiple courses of IV AGs. This study aimed to empirically test a pharmacokinetic (PK) model using Bayesian estimation of drug exposure in the deeper body tissues to determine feasibility for prediction of ototoxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>IV doses (n\u200a=\u200a3645) of tobramycin and vancomycin were documented with precise timing from 38 patients with CF (aged 8\u201321\u2009years), including total doses given and total exposure (cumulative AUC). Concentration results were obtained at 3 and 10\u2009h for the central (C1) compartment. These variables were used in Bayesian estimation to predict trough levels in the secondary tissue compartments (C2 trough) and maximum concentrations (C2max). The C1 and C2 measures were then correlated with hearing levels in the extended high-frequency range.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with more severe hearing loss were older and had a higher number of tobramycin C2max concentrations &amp;gt;2\u2009mg\/L than patients with normal or lesser degrees of hearing loss. These two factors together significantly predicted average high-frequency hearing level (r\u200a=\u200a0.618, P\u200a&amp;lt;\u200a0.001). Traditional metrics such as C1 trough concentrations were not predictive. The relative risk for hearing loss was 5.8 times greater with six or more tobramycin courses that exceeded C2max concentrations of 3\u2009mg\/L or higher, with sensitivity of 83% and specificity of 86%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Advanced PK model-informed analysis predicted ototoxicity risk in patients with CF treated with tobramycin and demonstrated high test prediction.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkab288","type":"journal-article","created":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T03:14:36Z","timestamp":1627010076000},"page":"2923-2931","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis"],"prefix":"10.1093","volume":"76","author":[{"given":"Min","family":"Dong","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"},{"name":"Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea A","family":"Blankenship","sequence":"additional","affiliation":[{"name":"Communication Sciences Research Center, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"McPhail","sequence":"additional","affiliation":[{"name":"Division of Pulmonary Medicine, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander A","family":"Vinks","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"},{"name":"Department of Pediatrics, College of Medicine, University of Cincinnati, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa L","family":"Hunter","sequence":"additional","affiliation":[{"name":"Communication Sciences Research Center, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH, USA"},{"name":"Department of Otolaryngology, University of Cincinnati Academic Medical Center, Cincinnati, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,8,11]]},"reference":[{"key":"2021121700290736200_dkab288-B1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3389\/fncel.2017.00325","article-title":"Towards the prevention of aminoglycoside-related hearing loss","volume":"11","author":"O\u2019Sullivan","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"2021121700290736200_dkab288-B2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/cb3005116","article-title":"Aminoglycoside antibiotics in the 21st century","volume":"8","author":"Becker","year":"2013","journal-title":"ACS Chem Biol"},{"key":"2021121700290736200_dkab288-B3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3389\/fncel.2017.00308","article-title":"Aminoglycoside-induced cochleotoxicity: a review","volume":"11","author":"Jiang","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"2021121700290736200_dkab288-B4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1517\/17460441.2011.562887","article-title":"The design and screening of drugs to prevent acquired sensorineural hearing loss","volume":"6","author":"Mukherjea","year":"2011","journal-title":"Expert Opin Drug Discov"},{"key":"2021121700290736200_dkab288-B5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1164\/rccm.200109-012CC","article-title":"Aminoglycoside prescribing and surveillance in cystic fibrosis","volume":"167","author":"Tan","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2021121700290736200_dkab288-B6","first-page":"262","article-title":"National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations","volume":"16","author":"Prescott","year":"2011","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2021121700290736200_dkab288-B7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/14992027.2010.524253","article-title":"Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: a study using extended high-frequency audiometry and distortion product otoacoustic emissions","volume":"50","author":"Al-Malky","year":"2011","journal-title":"Int J Audiol"},{"key":"2021121700290736200_dkab288-B8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jcf.2017.01.006","article-title":"The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis","volume":"16","author":"Garinis","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2021121700290736200_dkab288-B9","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/0194599818782444","article-title":"Progressive hearing loss among patients with cystic fibrosis and parenteral aminoglycoside treatment","volume":"159","author":"Zettner","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"key":"2021121700290736200_dkab288-B10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1755-7682-1-24","article-title":"Pulmonary bacterial pathogens in cystic fibrosis patients and antibiotic therapy: a tool for the health workers","volume":"1","author":"Coutinho","year":"2008","journal-title":"Int Arch Med"},{"key":"2021121700290736200_dkab288-B11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejps.2011.10.022","article-title":"Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring","volume":"45","author":"Croes","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"2021121700290736200_dkab288-B12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijantimicag.2010.02.018","article-title":"Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients","volume":"36","author":"O\u2019Donnell","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2021121700290736200_dkab288-B13","first-page":"94","article-title":"Infection prevention and control in cystic fibrosis: one size fits all. The argument against","volume":"36","author":"Smyth","year":"2020","journal-title":"Paediatr Respir Rev"},{"key":"2021121700290736200_dkab288-B14","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1164\/rccm.200812-1845PP","article-title":"Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations","volume":"180","author":"Flume","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"2021121700290736200_dkab288-B15","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.4187\/respcare.02980","article-title":"A survey of extended-interval aminoglycoside dosing practices in United States adult cystic fibrosis programs","volume":"59","author":"Prescott","year":"2014","journal-title":"Respir Care"},{"key":"2021121700290736200_dkab288-B16","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)17906-9","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2014the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"key":"2021121700290736200_dkab288-B17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1365-2125.2007.03045.x","article-title":"Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis - a population pharmacokinetic study","volume":"65","author":"Hennig","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"2021121700290736200_dkab288-B18","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1002\/ppul.25037","article-title":"Area under the curve achievement of once daily tobramycin in children with cystic fibrosis during clinical care","volume":"55","author":"Brockmeyer","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2021121700290736200_dkab288-B19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40262-018-0707-9","article-title":"Monitoring of tobramycin exposure: what is the best estimation method and sampling time for clinical practice?","volume":"58","author":"Gao","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2021121700290736200_dkab288-B20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cpt.339","article-title":"Therapeutic optimization as part of the precision medicine paradigm","volume":"99","author":"Vinks","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"2021121700290736200_dkab288-B21","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/AAC.47.3.1010-1016.2003","article-title":"Aminoglycoside nephrotoxicity: modeling, simulation, and control","volume":"47","author":"Rougier","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121700290736200_dkab288-B22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.13.4.649","article-title":"Accumulation pharmacokinetics of tobramycin","volume":"13","author":"Schentag","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121700290736200_dkab288-B23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/FTD.0000000000000023","article-title":"A two-compartment population pharmacokinetic-pharmacodynamic model of digoxin in adults, with implications for dosage","volume":"36","author":"Jelliffe","year":"2014","journal-title":"Ther Drug Monit"},{"key":"2021121700290736200_dkab288-B24","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/jac\/dkw351","article-title":"Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis","volume":"72","author":"Downes","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021121700290736200_dkab288-B25","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s00467-015-3097-3","article-title":"Risk factors for acute kidney injury during aminoglycoside therapy in patients with cystic fibrosis","volume":"30","author":"Downes","year":"2015","journal-title":"Pediatr Nephrol"},{"key":"2021121700290736200_dkab288-B26","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijantimicag.2013.11.006","article-title":"Dose optimisation of antibiotics in children: application of pharmacokinetics\/pharmacodynamics in paediatrics","volume":"43","author":"Downes","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2021121700290736200_dkab288-B27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/cpt1977223364","article-title":"Renal clearance and tissue accumulation of gentamicin","volume":"22","author":"Schentag","year":"1977","journal-title":"Clin Pharmacol Ther"},{"key":"2021121700290736200_dkab288-B28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2125.2001.00377.x","article-title":"The therapeutic monitoring of antimicrobial agents","volume":"52 Suppl 1","author":"Begg","year":"2001","journal-title":"Br J Clin Pharmacol"},{"key":"2021121700290736200_dkab288-B29","year":"2009"},{"key":"2021121700290736200_dkab288-B30","year":"1994"},{"key":"2021121700290736200_dkab288-B31","first-page":"397","article-title":"Early detection of ototoxicity using high-frequency, tone-burst-evoked auditory brainstem responses","volume":"3","author":"Fausti","year":"1992","journal-title":"J Am Acad Audiol"},{"key":"2021121700290736200_dkab288-B32","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archotol.1993.01880180081015","article-title":"High-frequency monitoring for early detection of cisplatin ototoxicity","volume":"119","author":"Fausti","year":"1993","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"2021121700290736200_dkab288-B33","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1055\/s-0040-1715935","article-title":"Early detection of ototoxicity using 1\/6th-octave steps","volume":"14","author":"Fausti","year":"2003","journal-title":"J Am Acad Audiol"},{"key":"2021121700290736200_dkab288-B34","year":"1999"},{"key":"2021121700290736200_dkab288-B35","volume-title":"Comprehensive Handbook of Pediatric Audiology","author":"Hunter","year":"2017","edition":"2nd edn"},{"key":"2021121700290736200_dkab288-B36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1044\/1059-0889(1998\/014)","article-title":"Tympanometric screening norms for adults","volume":"7","author":"Roup","year":"1998","journal-title":"Am J Audiol"},{"key":"2021121700290736200_dkab288-B37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1044\/jshd.1703.321","article-title":"Development of materials for speech audiometry","volume":"17","author":"Hirsh","year":"1952","journal-title":"J Speech Hear Disord"},{"key":"2021121700290736200_dkab288-B38","year":"2015"},{"key":"2021121700290736200_dkab288-B39","doi-asserted-by":"crossref","DOI":"10.1044\/2020_AJA-20-00059","article-title":"Functional impacts of aminoglycoside treatment on speech perception and extended high-frequency hearing loss in cystic fibrosis","author":"Blankenship","year":"2021","journal-title":"Am J Audiol"},{"key":"2021121700290736200_dkab288-B40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0010-4825(92)90011-B","article-title":"MW\/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring","volume":"22","author":"Proost","year":"1992","journal-title":"Comput Biol Med"},{"key":"2021121700290736200_dkab288-B41","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fphar.2020.00620","article-title":"Software tools for model-informed precision dosing: how well do they satisfy the needs?","volume":"11","author":"Kantasiripitak","year":"2020","journal-title":"Front Pharmacol"},{"key":"2021121700290736200_dkab288-B42","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s40262-012-0020-y","article-title":"Benchmarking therapeutic drug monitoring software: a review of available computer tools","volume":"52","author":"Fuchs","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2021121700290736200_dkab288-B43","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1097\/FTD.0000000000000214","article-title":"Retrospective evaluation of milrinone pharmacokinetics in children with kidney injury","volume":"37","author":"Gist","year":"2015","journal-title":"Ther Drug Monit"},{"key":"2021121700290736200_dkab288-B44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40262-013-0036-y","article-title":"Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis","volume":"52","author":"Hennig","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"2021121700290736200_dkab288-B45","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jac\/dkf168","article-title":"Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis","volume":"50","author":"Aminimanizani","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2021121700290736200_dkab288-B46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2021121700290736200_dkab288-B47","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2021121700290736200_dkab288-B48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.32614\/RJ-2016-042","article-title":"easyROC: an interactive web-tool for ROC curve analysis using R language environment","volume":"8","author":"Goksuluk","year":"2016","journal-title":"R J"},{"key":"2021121700290736200_dkab288-B49","doi-asserted-by":"crossref","first-page":"6698","DOI":"10.1128\/AAC.01131-16","article-title":"Bayesian estimation of tobramycin exposure in patients with cystic fibrosis","volume":"60","author":"Barras","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121700290736200_dkab288-B50","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40262-017-0610-9","article-title":"Evaluation of tobramycin exposure predictions in three Bayesian forecasting programmes compared with current clinical practice in children and adults with cystic fibrosis","volume":"57","author":"Burgard","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"2021121700290736200_dkab288-B51","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jcf.2020.07.001","article-title":"Prospective cohort study of ototoxicity in persons with cystic fibrosis following a single course of intravenous tobramycin","volume":"20","author":"Garinis","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2021121700290736200_dkab288-B52","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/j.1552-4604.1994.tb03995.x","article-title":"Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis","volume":"34","author":"Cooney","year":"1994","journal-title":"J Clin Pharmacol"},{"key":"2021121700290736200_dkab288-B53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"key":"2021121700290736200_dkab288-B54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijporl.2019.02.002","article-title":"Genetic susceptibility to aminoglycoside ototoxicity","volume":"120","author":"Nguyen","year":"2019","journal-title":"Int J Pediatr Otorhinolaryngol"},{"key":"2021121700290736200_dkab288-B55","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10162-011-0288-x","article-title":"TRPA1-mediated accumulation of aminoglycosides in mouse cochlear outer hair cells","volume":"12","author":"Stepanyan","year":"2011","journal-title":"J Assoc Res Otolaryngol"},{"key":"2021121700290736200_dkab288-B56","doi-asserted-by":"crossref","first-page":"eaaw1836","DOI":"10.1126\/sciadv.aaw1836","article-title":"Inflammation up-regulates cochlear expression of TRPV1 to potentiate drug-induced hearing loss","volume":"5","author":"Jiang","year":"2019","journal-title":"Sci Adv"},{"key":"2021121700290736200_dkab288-B57","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1242\/jcs.023705","article-title":"TRPV4 enhances the cellular uptake of aminoglycoside antibiotics","volume":"121","author":"Karasawa","year":"2008","journal-title":"J Cell Sci"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/2923\/41781503\/dkab288.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/76\/11\/2923\/41781503\/dkab288.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T21:51:35Z","timestamp":1725486695000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/11\/2923\/6348045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,11]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,8,11]]},"published-print":{"date-parts":[[2021,10,11]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab288","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,8,11]]}}}